Ultragenyx Pharmaceutical (RARE) Competitors

Genmab A/S (NASDAQ:GMAB) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Does the media prefer GMAB or RARE?

In the previous week, Ultragenyx Pharmaceutical had 5 more articles in the media than Genmab A/S. MarketBeat recorded 19 mentions for Ultragenyx Pharmaceutical and 14 mentions for Genmab A/S. Ultragenyx Pharmaceutical's average media sentiment score of 1.16 beat Genmab A/S's score of 1.09 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	12 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor GMAB or RARE?

Ultragenyx Pharmaceutical received 671 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 77.52% of users gave Ultragenyx Pharmaceutical an outperform vote while only 63.02% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 167 63.02%	Underperform Votes 98 36.98%
Ultragenyx Pharmaceutical	Outperform Votes 838 77.52%	Underperform Votes 243 22.48%

Do insiders & institutionals believe in GMAB or RARE?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more risk & volatility, GMAB or RARE?

Genmab A/S has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

Do analysts prefer GMAB or RARE?

Genmab A/S currently has a consensus price target of $39.17, indicating a potential upside of 85.58%. Ultragenyx Pharmaceutical has a consensus price target of $92.79, indicating a potential upside of 140.31%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Ultragenyx Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Which has higher valuation & earnings, GMAB or RARE?

Genmab A/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$21.53B	0.63	$1.14B	$1.74	12.13
Ultragenyx Pharmaceutical	$560.23M	6.47	-$569.18M	-$6.34	-6.09

Is GMAB or RARE more profitable?

Genmab A/S has a net margin of 36.30% compared to Ultragenyx Pharmaceutical's net margin of -101.60%. Genmab A/S's return on equity of 16.78% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	36.30%	16.78%	13.79%
Ultragenyx Pharmaceutical	-101.60%	-193.80%	-38.15%

Summary

Ultragenyx Pharmaceutical beats Genmab A/S on 10 of the 19 factors compared between the two stocks.